



Proteomics International

LABORATORIES LTD

ASX Release

12 September 2018

ASX code: PIQ

Proteomics International to receive \$928k from sale of shareholding in CPR Pharma Services

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) announces it will receive a boost to its balance sheet with the cash sale of its shareholding in CPR Pharma Services Pty Ltd (CPR).

- **Proteomics International to receive \$928,399 for its shareholding in CPR**
- **MOU between Proteomics International and CPR remains in place, targeting advanced diagnostics and analytical services for clinical trials**

Proteomics International has received notice that an offer to purchase all the shares of CPR has been received and accepted by CPR's majority shareholder. In accordance with the drag along provisions of the Shareholder Agreement, Proteomics International will receive \$928,399 for its shareholding in CPR. The sale is due to settle on or about 30 September 2018.

In March 2018 Proteomics International issued 3,868,305 ordinary PIQ shares (at a deemed issue price of \$0.3045) to acquire 10% of the fully diluted issued share capital of CPR [ASX: 5 Mar 2018]. The sale therefore equates to receipt of \$0.24 per PIQ share issued. The issued shares will remain in escrow until 4 March 2019.

The MOU between Proteomics International and CPR remains in place, targeting advanced diagnostics and analytical services for clinical trials [ASX: 2 February 2018].

ENDS

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Susan Fitzpatrick-Napier
[Public Relations & Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests, and offset the cash burn from R&D and product development through provision of specialist analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com